Breast, Breast Neoadjuvant
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Eligible for screening study DCP 001
Randomization to the fulvestrant arm (Arm 2) and the anastrozole + fulvestrant arm (Arm 3) will be closed to new patient accrual on 11/01/2018; accrual to these two arms has been met per protocol. Beginning on 11/01/2018 all new patients registered to A011106 will be registered to the anastrozole arm (Arm 1).
A011106 is soon expected to reach its accrual goal. Therefore, EFFECTIVE THURSDAY, May 9, 2019 at 4:30 PM ET, A011106 will be temporarily suspended to new patient registration as the study team evaluates the current accrual and study design.